Shares of Ocular Therapeutix rose sharply following market rumors that Sanofi is preparing a larger acquisition offer, signaling renewed investor interest in the ophthalmic drug developer. The stock’s momentum reflects growing confidence in a potential strategic transaction.
- Ocular Therapeutix (OTX) shares rose 18% on January 15, 2026, on acquisition rumors
- Sanofi is reportedly considering a bid exceeding $1.8 billion, up from an initial $1.5 billion offer
- Dextenza implant and next-gen delivery platform are key drivers of valuation
- FDA approval for dry eye disease and strong clinical data support acquisition rationale
- Market share in ophthalmology is expected to reach $45 billion by 2030
- Trading volume surged over 200% above average, signaling heightened investor activity
Ocular Therapeutix (OTX) saw its shares climb more than 18% in early trading on January 15, 2026, amid widespread speculation about a potential expansion of Sanofi’s takeover bid. The rally came after anonymous sources within financial circles reported that Sanofi was evaluating a revised offer exceeding the initial $1.5 billion proposal made in late 2025. Analysts note that the company’s proprietary sustained-release drug delivery platform, particularly its Dextenza implant for post-surgical ocular inflammation, remains a key asset in attracting higher bids. The initial offer, valued at approximately $1.5 billion, represented a 35% premium over Ocular Therapeutix’s average stock price over the prior 30 trading days. If the revised bid is confirmed, it could push the total value toward $1.8 billion, reflecting increased strategic urgency from Sanofi to strengthen its portfolio in ophthalmology. The company’s recent FDA approval of Dextenza for dry eye disease and strong Phase 3 trial results for its next-generation sustained-release formulation have bolstered its valuation. Investors are also assessing the broader implications of a larger acquisition, particularly on Sanofi’s R&D pipeline and commercial footprint in specialty eye care. With the global market for ophthalmic therapeutics projected to exceed $45 billion by 2030, the acquisition could accelerate Sanofi’s entry into high-growth niche markets. Meanwhile, Ocular Therapeutix’s board has not publicly commented on the rumors, though insiders suggest discussions are ongoing. The stock’s performance has drawn attention from institutional traders and hedge funds, with volume increasing by over 200% above average. Analysts at major firms have revised their price targets upward, citing a 70% probability of a successful deal, with the acquisition likely to close by mid-2026 if finalized.